Guanxinping Tablets Inhibit ET-1-Induced Proliferation and Migration of MOVAS by Suppressing Activated PI3K/Akt/NF-κB Signaling Cascade

Ying-Ying Wu,1 Yi-Lin Huang,2 Bin Dai,1 Jian-Wei Liu,2 and Xu Han2

1 Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou 215000, China
2 Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China

Correspondence should be addressed to Xu Han; hanxu9998@126.com

Received 5 May 2021; Revised 7 November 2021; Accepted 15 May 2022; Published 31 May 2022

Copyright © 2022 Ying-Ying Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background/Aim. Abnormal proliferation and migration of vascular smooth muscle cells is one of the main causes of atherosclerosis (AS). Therefore, the suppression of abnormal proliferation and migration of smooth muscle cells are the important means for the prevention and inhibition of AS. The clinical effects of Guanxinping (GXP) tablets and preliminary clinical research on the topic have proved that GXP can effectively treat coronary heart disease, but its underlying mechanism remains unclear. This study aimed to confirm the inhibitory effect of GXP on the abnormal proliferation of mouse aortic vascular smooth muscle (MOVAS) cells and to explore the underlying mechanism. Methods. MOVAS cells were divided into two major groups: physiological and pathological groups. In the physiological group, MOVAS cells were directly stimulated with GXP, whereas in the pathological group, the cells were stimulated by endothelin-1 (ET-1) before intervention by GXP. At the same time, atorvastatin calcium, which effectively inhibits the abnormal proliferation of MOVAS cells, was used in the negative control group. CCK8 assay, scratch test, ELISA, Western blotting, and immunofluorescence staining were performed to observe the proliferation and migration of MOVAS cells and the expression levels of related factors after drug intervention in each group.

Results. In the physiological group, GXP had no significant effect on the proliferation and migration of MOVAS cells and the related factors. In the pathological group, a high dose of GXP reduced the abnormal proliferation and migration of MOVAS cells. Further, it reduced the expression levels of PI3K; inhibited the phosphorylation of Akt (protein kinase B); upregulated IκB-α levels; prevented nuclear factor kappa B (NF-κB) from entering the nucleus; downregulated the expression of interleukin 6 (IL6), IL-1β, and iNOS; and upregulated the ratio of apoptosis-related factor Bax/Bcl-2. There was no significant difference between the high-dose GXP group and the atorvastatin calcium group (negative control group). Conclusion. Our findings revealed that GXP was able to inhibit the proliferation and migration of MOVAS cells by regulating the PI3K/Akt/NF-κB pathway.

1. Introduction

The proliferation and migration of vascular smooth muscle cells (VSMCs) is one of the main causes of atherosclerosis (AS). Under physiological conditions, VSMCs regulate vascular tension and blood pressure. VSMCs proliferate and migrate excessively and secrete inflammatory factors under conditions of vascular injury, inflammation, and oxidative stress [1]. Therefore, we only need to inhibit the proliferation and migration of smooth muscle cells in the pathological state but not in the physiological state.

ET-1 is a peptide synthesized by endothelial cells, which can accelerate the AS process. In the physiological state, ET-1 releases nitric oxide (NO) and prostacyclin by binding to endothelin type A (ETA) and endothelin B (ETB) receptors, thus regulating the relaxation, proliferation, and migration of VSMCs. In a pathological state, ETA and ETB receptors are highly expressed in vascular smooth muscles, stimulating smooth muscle cells to contract, proliferate, and migrate [2, 3]. Atorvastatin calcium is one of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, which plays an antiatherosclerotic role by reducing plasma lipids.
Further, atorvastatin calcium can inhibit the proliferation and migration of VSMCs by inhibiting PI3K/Akt signaling pathway but has no obvious effect on VSMCs in a physiological state [5].

Akt, a member of serine threonine kinase, has three different subtypes: Akt1, Akt2, and Akt3, which play an important role in cell proliferation and survival [6]. PI3K is the upstream signaling factor of Akt, which promotes Akt phosphorylation by activating t308 and s473. PI3K/Akt can affect the process of AS by regulating the proliferation and migration of smooth muscle cells [7]. The activation of PI3K/Akt signaling can affect macrophage apoptosis by promoting antiapoptotic factors Bcl-xl and Bcl-2 and inhibiting proapoptotic factor Bcl-2-associated X (Bax); thus, it is a key determinant of the number of atherosclerotic plaque cells [8]. Furthermore, NF-κB, a key nuclear factor, which usually combines with inhibitor of κB (IκB) to maintain an inactive state, can mediate cell proliferation and apoptosis [9]. NF-κB is implicated in multiple pathological processes of atherogenesis, such as inflammation, oxidative stress, and VSMC proliferation [10]. Accordingly, the expression of NF-κB increases when PI3K/Akt signaling pathway is activated [11].

GXP is the experience prescription by Qi-yi Li, a famous Chinese Medicine professor. Professor Li summed up the theory of Gualou xiebai baijiu decoction in the synopsis of prescriptions of the golden chamber and the Danggui buxue decoction in the differentiation of endogenous and exogenous diseases. Gualou xiebai baijiu decoction and Danggui buxue decoction have been widely used to treat coronary heart disease.

Subsequently, Li added and removed two prescriptions to get GXP. GXP is a composition of five herbs, including Polygonatum sibiricum, Angelica sinensis, Panax notoginseng (Burkill) F.H.Chen, Trichosanthes kirilowii Maxim. Peel, and Nardostachys chinensis, and has been used clinically for decades; it has also been approved as a hospital preparation since 2001. The quality of GXP can be controlled [12, 13]. Through analyses via LC-MS/MS and LCMS-Q-TOF methods, it can be concluded that in the charge quality comparison plot (M/Z: 200–750), there are many components and concentrations of ethyl acetate extracted species, especially Nardostachys chinensis and Trichosanthes kirilowii Maxim. Peel, in the large range of charge mass ratio (M/Z: 750–1200); the n-butanol extract has more components and higher concentrations of particularly Angelica sinensis and Panax notoginseng (Burkill) F.H.Chen [14]. The effective components of GXP are mainly Notoginsenoside R1, Ginsenoside Rg1, and Ginsenoside Rb1 [12]. Previous network pharmacological studies have shown that GXP is closely associated with Akt and IL-6 (Table 1, Figure 1). Combined with previous studies, it can be seen that GXP can reduce the expression of NF-κB. Accordingly, we next speculated whether the antiatherosclerotic effect of GXP is associated with the PI3K/Akt/NF-κB pathway. Thus, we studied the relationship between the effect of GXP on the proliferation and migration of VSMCs and PI3K/Akt/NF-κB pathway [15].

<table>
<thead>
<tr>
<th>Key target</th>
<th>Target name</th>
<th>Betweenness</th>
<th>Closeness</th>
<th>Degree</th>
</tr>
</thead>
<tbody>
<tr>
<td>INS</td>
<td>Insulin</td>
<td>0.074702</td>
<td>0.866197</td>
<td>104</td>
</tr>
<tr>
<td>IL6</td>
<td>Interleukin 6</td>
<td>0.032431</td>
<td>0.831081</td>
<td>98</td>
</tr>
<tr>
<td>AKT1</td>
<td>Serine-threonine protein kinase 1</td>
<td>0.031843</td>
<td>0.825503</td>
<td>97</td>
</tr>
<tr>
<td>VEGFA</td>
<td>Vascular endothelial growth factor A</td>
<td>0.018029</td>
<td>0.793548</td>
<td>91</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumor necrosis factor</td>
<td>0.020198</td>
<td>0.788462</td>
<td>90</td>
</tr>
<tr>
<td>TP53</td>
<td>Tumor protein 53</td>
<td>0.015012</td>
<td>0.763975</td>
<td>85</td>
</tr>
<tr>
<td>EGF</td>
<td>Epidermal growth factor</td>
<td>0.021643</td>
<td>0.759259</td>
<td>84</td>
</tr>
<tr>
<td>JUN</td>
<td>Jun proto-oncogene</td>
<td>0.010376</td>
<td>0.754601</td>
<td>83</td>
</tr>
</tbody>
</table>

2 Materials and Methods

2.1 Animal and Preparation of Medicated Serum. All experimental protocols in this study were approved by the Ethics Committee of Jiangsu Province Hospital of Chinese Medicine. All procedures were performed in accordance with ethical standards and laboratory care by the National Institute of Health, China. 6-week-old male Sprague-Dawley rats, weighing 200–220 g, were purchased from Hangzhou Medical College, Zhejiang, CHN (SCXK2019-0002). The dosage for each mouse was according to the human and rat dosage conversion formula: rat dosage (mg/kg) = human (70 kg) dosage × 0.018/0.2 kg. GXP group was given GXP tablets (2.43 g/kg-bid, Jiangsu Province Hospital of Chinese Medicine, CHN), atorvastatin calcium group was given atorvastatin calcium (0.018 g/kg-bid, Lepu, CHN), control group was given equal volume of distilled water [16, 17]. Fasting for 12 h after 3 days of intragastric administration, and 1 h after intragastric administration on the 4th day, mice
were anesthetized by inhalation of ether. Blood was taken from the abdominal aorta to obtain medicated serum. During the experiment, every effort was made to minimize the pain of animals [18].

2.2. Cell Culture. Mouse aortic vascular smooth muscle cells (MOVAS, ACTT number:CRL-2797) and FBS were purchased from Cellcook Biotech Co., China. MOVAS were cultured in DMEM (Gibco, USA) medium containing 10% FBS, 0.2 mg/ml G418 (BioFroxx, GER), penicillin, and streptomycin (Gibco, USA, 1 : 100) at 37°C and 5% CO₂. The cells were divided into physiological group and pathological group. The physiological group included the control group (blank group), low- and high-dose GXP groups, and atorvastatin calcium group. The pathological group included endothelin-induced ET-1 group (model group), ET-1 + low- and high-dose GXP groups, and ET-1 + atorvastatin calcium group.

2.3. Safety and Toxicity Assay. For the CCK-8 assay, cells were seeded in 96-well culture plates (4000 cells/well). All these plates were shaken back and forth with a figure “eight” to distribute the cells evenly and then incubated for 12 h in a 37°C incubator to make them adherent. The media of each group were replaced with the medium containing 2% FBS (treated with serum starvation) for 12 h. Then, 96-well culture plates were divided into four groups. Each group was added separately with 1%, 10%, and 20% medicated serum of GXP or 10% medicated serum of atorvastatin calcium. After that, the original mediums were replaced by mediums containing 10% CCK-8. An automatic microplate reader (BIOTEK, USA) was used to determine the absorbance at 490 nm when 0 h, 12 h, 24 h, 48 h, and 72 h incubation in the dark.

2.4. Cell Viability Assay. For the CCK-8 assay, cells were seeded in 96-well culture plates (4000 cells/well). All these plates were shaken back and forth with a figure “eight” to distribute the cells evenly and then incubated for 12 h in a 37°C incubator to make them adherent. The media of each group were replaced with the medium containing 2% FBS (treated with serum starvation) for 12 h. Then, each well of the pathological group was intervened with ET-1 (10-4 mmol/L, Aladdin CHN) [19] for 24 h. Then, the blank group and the model group were added with 10% blank rat serum. The low- and high-dose GXP groups were added with 1% and 10% medicated serum of GXP. The ET-1 + low- and high-dose GXP groups were added with 1% and 10% medicated serum of GXP as well. Both atorvastatin calcium group and ET-1 + atorvastatin calcium group were added with 10% medicated serum of atorvastatin calcium. The corresponding serum stimulated each group for 48 h. After 48 h, the original mediums were replaced by mediums containing 10% CCK-8. An automatic microplate reader (BIOTEK, USA) was used to determine the absorbance at 490 nm after 3 h incubation in the dark [20].

2.5. Wound Healing Assay. A straight line was drawn on the bottom of the culture dish. MOVAS were subcultured in 8 culture dishes. MOVAS were treated with serum starvation for 24 h after reaching about 80% of the culture dishes. After that, the media of each group were replaced with the medium containing 2% FBS (treated with serum starvation) for 12 h. In the pathological group, MOVAS were treated with ET-1 for 24 hours. The 200 μl sterile pipette tip was used to make a scratch along the ruler, which was perpendicular to the straight line of the bottom. Then, the blank group and the model group were added with 10% blank rat serum. The low- and high-dose GXP groups were added with 1% and 10% medicated serum of GXP. The ET-1 + low- and high-dose GXP groups were added with 1% and 10% medicated serum of GXP as well. Both atorvastatin calcium group and ET-1 + atorvastatin calcium group were added with 10% medicated serum of atorvastatin calcium. The corresponding serum stimulated each group for 48 h. The scratch conditions were photographed at 0 h, 24 h, and 48 h, and the scratch area was calculated by Image J 1.53 software (NIH, USA) [21].

2.6. ELISA Assay. Same as the previous experiments, MOVAS were treated with starvation for 12 h. ET-1 induced MOVAS of the pathological group for 24 h. And then, the corresponding drugs stimulated each group for 48 h. Then, the supernatant of the cell culture medium was collected. The expression of inflammatory factors (IL-6, IL-1β, and TNF-α) levels in the cell culture medium was assayed by ELISA kit (Thermo Fisher Scientific, USA) according to the instructions [22].

2.7. Western Blot Analysis. Same as the previous experiments, MOVAS were treated with starvation for 12 h. ET-1 induced MOVAS of the pathological group for 24 h. And then, the corresponding drugs stimulated each group for 48 h. Protein was extracted from lysed cells. When we detected NF-κB, we extracted the nuclear protein from MOVAS. While assaying other factors, the total protein was extracted. The SDS-PAGE gel was prepared with a gel preparation kit (Servicebio, CHN). The samples of each group were separated by SDS gel electrophoresis and then transferred to nitrocellulose membranes, added the primary antibodies overnight after blocking and incubation, and incubated with secondary antibody for 1 h the next day. Protein signals were visualized by ChemiDoc System (BioRad). ImageJ 1.53 software was used to calculate the gray value. The main antibodies used in this study are anti-Pi3K (Proteintech, CHN, 1: 3000), anti-Akt (Proteintech, 1: 1000), anti-phospho-Akt (Proteintech, 1: 2000), anti-IkB-α (Cell Signaling Technology, USA, 1: 1000), anti-NF-κB (Proteintech, 1: 2000), anti-Bax (CST, 1: 1000), anti-VCAM-1 (Proteintech, 1: 1000), anti-GAPDH (Proteintech, 1: 5000), anti-H3 (Proteintech, 1: 1000), anti-iNOS (CST, 1: 1000), anti-TNF-α (CST, 1: 1000), anti-Rabbit IgG (Servicebio, 1: 3000), and anti-Mouse IgG (Servicebio, 1: 3000) [23, 24].
2.8. **Immunofluorescence Staining.** MOVAS were inoculated in a 12-well plate. After 12 h of culture, cells were treated in the same way as the previous experiment. Both the physiological group and the pathological group were treated with starvation for 12 h. ET-1 induced MOVAS of the pathological group for 24 h. And then, the corresponding drugs stimulated each group for 48 h. After fixing, rupturing, and blocking, we added the primary antibody (anti-NF-κB, Proteintech, 1:500) in a plate overnight at 4°C, then incubated with fluorescent secondary antibody (anti-Rabbit IgG, Servicebio, 1:400) for 1 h at room temperature and dark. Incubated with DAPI (Servicebio) at room temperature for 10 min, mount the slide with antifluorescence quenching solution. The fluorescence photos were photographed under fluorescent microscopy (NIKON, JPN), and then, ImageJ 1.53 software was used to count the fluorescence brightness [25].

2.9. **Statistical Analysis.** Each of the above experiments was carried out three times or more independently repeated experiments. Data are reported as the mean ± standard deviation (SD). The data of different magnitude was normalized and subjected to one-way analysis of variance (ANOVA) and used SPSS 25.0 statistical software (IBM, USA). P-value < 0.05 was considered significant.

3. Results

3.1. **Safety and Toxicity of GXP.** The safety and toxicity of GXP were measured by CCK8. Cell viability at different concentrations and intervention times showed that 1% and 10% medicated serum of GXP and 10% medicated serum of atorvastatin calcium showed no obvious toxicity within 48 hours (Figure 2).

3.2. **Effect of GXP on the Survival Rate of MOVAS.** In this experiment, CCK8 assay was used to measure the cell survival rate of each group (Figure 3(a)). In the physiological group, there was no significant difference in cell survival rate between each group. It indicated that GXP had no significant effect on cell survival rate under the physiological state of MOVAS. The survival rate of the cells was significantly increased after stimulation with ET-1 (cell viability, 137.6 ± 17.14%, n = 3 (P < 0.01 as control)). It showed that ET-1 led to abnormal proliferation of MOVAS. After the treatment of the high dose of GXP, the survival rate of cells decreased significantly (cell viability, 105.1 ± 10.91%, n = 3 (P < 0.01 as model)). There was no significant difference between the high-dose GXP group and the atorvastatin calcium group. The results showed that high-dose GXP could inhibit the abnormal proliferation of MOVAS, and its effect was no less than atorvastatin calcium.

3.3. **Effect of GXP on the Mobility of MOVAS.** The mobility of MOVAS was evaluated by wound healing assay (Figure 3(b)). According to the formula, 24 h mobility = (0 h scratch area – 24 h scratch area)/0 h scratch area, and the mobility of each group was calculated. At the 24th hour, the migration rate of the model group was higher than the control group (relative migration rate, 42.78 ± 6.201%, n = 3 (P < 0.05)). But, there was no significant difference among the other groups (Figure 2(a)). At the 48th hour, there was still no difference among each group in the physiological group. In the pathological group, the mobility of the high-dose GXP group (relative migration rate, 62.94 ± 1.799%, n = 3 (P < 0.05 as model)) and atorvastatin calcium group (relative migration rate, 63.39 ± 1.809%, n = 3 (P < 0.05 as model)) was lower than that of the model group. There was no significant difference between the high-dose GXP group and the atorvastatin calcium group (Figure 2(b)). These results proved that high-dose GXP inhibited the excessive migration of MOVAS, and its effect was no less than that of atorvastatin calcium. At the same time, it was verified that the proliferation and migration of smooth muscle cells could be induced after being stimulated by ET-1 for 24 hours [19] while drugs needed 48 hours to stimulate the cells before they had an obvious effect. That provided the basis for the later experiment.

3.4. **Effect of GXP on the Expression of Inflammatory Factors in MOVAS.** ELISA assay was used to test the expression of IL-6, IL-1β, and TNF-α. The results showed that the levels of IL-6 and IL-1β in the physiological group were similar. In the pathological group, IL-6 (relative cytokine levels, 498.8 ± 8.128, n = 3 (P < 0.01)) and IL-1β (relative cytokine levels, 8.353 ± 0.3811, n = 3 (P < 0.01)) in the model group were much higher than those in the control group. High-dose GXP group and atorvastatin calcium group decreased the expression of IL-6 (relative cytokine levels, 422.8 ± 29.32, 428.2 ± 34.74, n = 3 (P < 0.05 as model)) and IL-1β (relative cytokine levels, 4.443 ± 0.2870, 4.130 ± 0.4727, n = 3 (P < 0.05 as model)) (Figure 4). TNF-α was measured more than three times, but no results have been detected yet. In this study, for the moment, TNF-α was not considered its effect on the proliferation and migration of MOVAS.
3.5. Effect of GXP on PI3K/Akt/NF-κB Pathway on the Expression of Related Proteins. We detected the level of PI3K/Akt/NF-κB pathway-related proteins by Western blot analysis (Figure 5). Besides, we also observed the nuclear translocation of NF-κB by immunofluorescence staining. We found that there was no significant difference in protein expression in the physiological group (Figure 5(b)). ET-1 activated PI3K/Akt/NF-κB pathway and gave rise to the changes in related proteins. In the pathological group, GXP reduced the expression of PI3K (0.7602 ± 0.2543, n = 3 (P < 0.01 as model)), inhibited the phosphorylation of Akt (1.095 ± 0.2712, n = 3 (P < 0.05 as model)), increased the level of 1xB-α expression (1.287 ± 0.1881, n = 3 (P < 0.05 as model)), upregulated Bax/Bcl-2 ratio (0.8657 ± 0.1050, n = 3 (P < 0.05 as model)), and decreased the expression of iNOS (1.064 ± 0.2859, n = 3 (P < 0.05 as model)) (Figure 5(c)).

3.6. Effect of GXP on the Entry of NF-κ to the Nucleus. After stimulated by ET-1, the expression of NF-κB (1.416 ± 0.1223, n = 3 (P < 0.05)) and fluorescence intensity (fluorescence intensity ratio, 1.378 ± 0.0369 n = 3 (P < 0.01)) in the nucleus increased. It showed that the level of NF-κB in the nucleus increased. After intervened by GXP (0.9309 ± 0.2151, n = 3 (P < 0.05)) (fluorescence intensity ratio, 1.070 ± 0.0893 n = 3 (P < 0.01)) or atorvastatin calcium, the fluorescence intensity in nucleus decreased. This proved that GXP inhibited the activation of NF-κB by ET-1 (Figure 6).
**Figure 4:** Effect of GXP on the expression of inflammatory factors in MOVAS. In the physiological group, other groups were compared with the control group, and in the pathological group, other groups were compared with the model group (ET-1 group). *P < 0.05, **P < 0.01 compared with the model group (ET-1 group).

**Figure 5:** Effect of GXP on PI3K/Akt pathway on the expression of related proteins. GXP inhibited the activation of ET-1 to PI3K/AKT signaling pathway. The protein expression levels of PI3K, Akt, pAkt, IκB-α, Bax/Bcl-2, and iNOS were determined by Western blotting. The graphs represent the relative activity of these proteins for three independent experiments. (a) The band and molecular weight of each protein in Western blotting; (b) the relative expression of each protein in the physiological group; (c) the relative expression of each protein in the pathological group. In the physiological group, other groups were compared with the control group, and in the pathological group, other groups were compared with the model group (ET-1 group). *P < 0.05, **P < 0.01 compared with the model group (ET-1 group).
4. Discussion

Many vascular diseases such as coronary heart disease, stroke, and intermittent claudication are all results of AS. Despite major advances in prevention measures, many individuals die of acute complications of AS [26]. Therefore, it is very significant to make further efforts to study the preventive measures of AS. VSMCs are an important part of blood vessels and are closely associated with AS. Endogenous levels of oxidative DNA damage in VSMCs promote atherosclerotic plaque formation [27]. VSMCs accelerate the formation of atherosclerotic plaques in the state of premature aging, which is induced by replicative failure and stress [28]. In addition, the dysregulation of the autophagy level of smooth muscle cells deteriorates AS [29]. Endogenous DNA oxidative damage, premature aging, and autophagy all affect the proliferation and migration of smooth muscle cells and aggravate AS. Nevertheless, VSMCs regulate vascular tension and blood pressure without obvious proliferative changes under physiological conditions [1].

In the past decades, more than 1,000 clinical studies on GXP have been conducted. They have proven the efficacy of GXP in improving the clinical symptoms and main biochemical standards of patients with coronary heart disease and the therapeutic effect in alleviating AS [30, 31]. Previous studies have shown that GXP plays an antiatherosclerotic role through multiple pathways. GXP reduces the level of NF-κB, regulates the apoptosis of endothelial cells, inhibits the M1 polarization of macrophages induced by LPS, promotes M2 polarization, increases the level of serum NO, and decreases the content of plasma ET in golden hamsters with...
coronary AS [15, 16, 32]. Based on previous studies, we authenticate the antiatherosclerotic effect of GXP. Although some mechanisms have been studied, attention needs to be paid to the relationship between smooth muscle cells and AS in studies related to GXP. As a result, we chose VSMCs as the research object, used in combination with previous research results, and used ET-1 as the inducer.

In this study, we observed that the survival rate and migration rate of MOVAS in the model group treated with ET-1 were higher than those in the blank group, and PI3K/Akt/NF-κB pathway was activated, which was consistent with the literature [33, 34]. GXP inhibited the proliferation and migration of MOVAS, which was remarkably induced by ET-1, and did not affect the physiological state of MOVAS. Meanwhile, GXP inhibited PI3K/Akt/NF-κB pathway, which was activated by ET-1 (Figure 7). In the pathological group, GXP reduced the expression of PI3K and inhibited Akt phosphorylation; subsequently, GXP increased the expression of iNOS; inhibited NF-κB from entering the nucleus; decreased the expression of IL-6, IL-1β, and iNOS; and raised the Bax/Bcl-2 ratio.

PI3K/Akt pathway is involved in cell growth, proliferation, and migration. PI3K/Akt pathway activation can lead to cell proliferation, migration, and even tumor development [35]. It is the signaling pathway of NF-κB, a family of transcription factors, promotes the inflammatory response, and regulates cell proliferation and apoptosis. Moreover, the NF-κB signaling pathway interacts with PI3K/Akt signaling pathway [36]. The activation of PI3K gives rise to Akt phosphorylation; further, pAkt activates the transformation and decomposition of 1kB-α, which breaks down the bond with NF-κB, resulting in a lower expression of 1kB-α, activation of NF-κB, and increased transfer of NF-κB to the nucleus [37]. In addition, activation of PI3K/Akt signaling pathway inhibits Bax and raises the levels of proteins Bcl-2 and iNOS. Bax is the main apoptotic protein, whereas Bcl-2 is an antiapoptotic protein [38]. Inducible nitric oxide synthase (iNOS) is one of the three subtypes of NOS. High concentration of endogenous NO produced by excessive iNOS promotes cell growth and metastasis, and low concentration of iNOS inhibits cell proliferation [39].

In this study, we also observed that ET-1 can upregulate the expression of inflammation-related factors IL-6 and IL-1β. Therefore, we consider that ET-1 not only promotes the proliferation and migration of MOVAS but also has a certain effect on inflammation. When the pathological group with increased inflammation was treated with GXP, IL-6 and IL-1β were downregulated. GXP inhibited the inflammatory response of MOVAS under pathological conditions. Given that inflammation of MOVAS is also associated with atherosclerosis, this may also be one of the ways that GXP exerts its antiatherosclerotic effects.

GXP is a composition of five herbs, including P. sibiricum, A. sinensis, P. notoginseng (Burkill) F. H. Chen, T. kirilowii Maxim. Peel, and N. chinensis. Studies have shown that all five herbal medicines are related to the PI3K/Akt pathway and NF-κB pathway. Dioscin, which was purified from P. sibiricum, can inhibit the PI3K/Akt pathway [40]. In contrast, a polysaccharide from P. sibiricum has been known for its enhancing effects on the PI3K/Akt signaling pathway [41]. In addition, studies have shown that a Polynatum polysaccharide can activate the NF-κB pathway [42]. Further, vascular Endothelial Growth Factor Receptor 2 (VEGFR2) activated PI3K/Akt signaling pathway can be greatly inhibited by the acetone extract of A. sinensis rich in phthalides [43]. Further, Angelica sinensis polysaccharide is a major bioactive component of A. sinensis. Phosphorylation levels of PI3K and Akt can be increased by A. sinensis polysaccharide by downregulating miR-22 in cells [44]. Besides, A. sinensis reduces the expression of NF-κB [45]. In addition to different kinds of drug extracts, different types of P. notoginseng saponins also showed different effects on the PI3K/Akt pathway. A major component of P. notoginseng (Burkill) F. H. Chen, notoginsenoside R1, may repress miR-21’s target PTEN by upregulating miR-21 and prevent the blockage of PI3K/Akt pathway [46]. In contrast, Notoginsenoside F1 inhibits PI3K/Akt pathway [47]. Furthermore, notoginsenoside R1 hinders NF-κB pathways by modulating Toll-like receptors 4 (TLR4) [48]. In studies concerning T. kirilowii Maxim. Peel and N. chinensis, it is also mentioned that these herbs have certain effects on PI3K/Akt and NF-κB pathways [49–51].

Different components in herbal medicine have different effects on PI3K/Akt and NF-κB pathways, including inhibition, activation, and bidirectional regulation. GXP, which is made up of five herbs, showed inhibitory effects on PI3K/Akt/NF-κB pathway, which was overactivated by ET-1 in MOVAS. This may be because of the mutual counteraction of drug components or the consistency after mutual influence. Considering the different subjects or inducers studied in various studies, it is not easy to draw a final conclusion. This may be the subtlety of the recipe. To clarify the relationship between these components, we considered that GXP should be divided into single drug components for further evaluation. In addition to the effect of GXP on the pathological state, we also observed that GXP had no intervention in the physiological group in MOVAS. Combined with previous research, we proved that smooth muscle cells have no obvious proliferation and migration in the physiological state; therefore, it is unnecessary to inhibit them [1]. This not only showed the drug safety of GXP but also showed that it targeted the pathological state in MOVAS. GXP and atorvastatin have the same effect in terms of inhibiting the proliferation and migration of MOVAS, which provides a new scheme for clinical combined prevention and treatment of atherosclerosis in the future.

There is another interesting discovery. In this study, we also observed that there was no significant change in TNF-α between groups after six independent experiments. We tested TNF-α in the cells again by Western blotting. There was still no band expression. Thus, for the time being, we will consider its relationship with cell characteristics of MOVAS. In follow-up experiments, we may make further observations and expect more interesting findings.
5. Conclusion

In this study, we confirm that GXPinhibitstheproliferation andmigrationofMOVASandtheactivationofPI3K/Akt/NF-κB pathway evoked by ET-1. Meanwhile, these twofactorshavebeenknowntoacceleratetheprocessofatherosclerosis. Therefore, we infer that GXPinhibits theproliferation and migration of VSMCs by inhibiting theactivation of PI3K/Akt/NF-κB pathway andfinallyplays anantiatheroscleroticrole.

Abbreviations

GXP: Guanxinping
AS: Atherosclerosis
ET-1: Endothelin-1
MOVAS: Mouse aortic vascular smooth muscle cells
VSMCs: Vascular smooth muscle cells
AKT: Protein kinase B
NF-κB: Nuclear factor kappa B
IκB: Inhibitor of κB
BAX: Bcl-2 associated X
NO: Nitric oxide
IL: Interleukin
TNF-α: Tumor necrosis factor-α.

Data Availability

Detailed data sets or any other information is available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Xu Han designed the research. Ying-ying Wu performed the experiment, analyzed the data, and drafted the manuscript. Bin Dai revised the manuscript. Yi-lin Huang and Jian-wei Liu assisted in the animal experiment. Yi-lin Huancompletedthethenetworkpharmacologicalstudies. All authors gave final approval and agreed to be accountable for all of this manuscript.

Acknowledgments

This work was supported by grants from Suzhou Science and Technology Development Plan Project (SKJYD2021122), Project of Jiangsu Natural Science Foundation (BK20181505), the third phase scientific research project of the dominant subject of traditional Chinese medicine in Nanjing University of Chinese Medicine (ZYX03KF032), and Special Plan for Science and Technology Development of Traditional Chinese Medicine in Jiangsu Province (2020ZX08).

References

Evidence-Based Complementary and Alternative Medicine


Evidence-Based Complementary and Alternative Medicine


